vTv Therapeutics, Inc. (VTVT)
30.58
+0.12
(+0.38%)
USD |
NASDAQ |
Sep 16, 16:00
30.58
0.00 (0.00%)
After-Hours: 20:00
vTv Therapeutics Enterprise Value : 33.33M for Sept. 15, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 15, 2026 | 33.33M |
| September 14, 2026 | 37.19M |
| September 11, 2026 | 39.28M |
| September 10, 2026 | 38.85M |
| September 09, 2026 | 44.48M |
| September 08, 2026 | 42.51M |
| September 04, 2026 | 44.72M |
| September 03, 2026 | 45.19M |
| September 02, 2026 | 44.91M |
| September 01, 2026 | 39.20M |
| August 31, 2026 | 39.40M |
| August 28, 2026 | 40.82M |
| August 27, 2026 | 42.55M |
| August 26, 2026 | 45.58M |
| August 25, 2026 | 46.92M |
| August 24, 2026 | 46.84M |
| August 21, 2026 | 44.34M |
| August 20, 2026 | 43.65M |
| August 19, 2026 | 42.92M |
| August 18, 2026 | 37.35M |
| August 17, 2026 | 36.68M |
| August 14, 2026 | 31.99M |
| August 13, 2026 | 34.87M |
| August 12, 2026 | 38.53M |
| August 11, 2026 | 43.50M |
| Date | Value |
|---|---|
| August 10, 2026 | 48.42M |
| August 07, 2026 | 52.67M |
| August 06, 2026 | 49.68M |
| August 05, 2026 | 48.81M |
| August 04, 2026 | 39.63M |
| August 03, 2026 | 40.93M |
| July 31, 2026 | 40.78M |
| July 30, 2026 | 42.08M |
| July 29, 2026 | 37.35M |
| July 28, 2026 | 35.77M |
| July 27, 2026 | 35.54M |
| July 24, 2026 | 34.40M |
| July 23, 2026 | 38.06M |
| July 22, 2026 | 38.10M |
| July 21, 2026 | 42.98M |
| July 20, 2026 | 40.90M |
| July 17, 2026 | 42.86M |
| July 16, 2026 | 40.54M |
| July 15, 2026 | 42.12M |
| July 14, 2026 | 38.93M |
| July 13, 2026 | 37.74M |
| July 10, 2026 | 45.27M |
| July 09, 2026 | 45.07M |
| July 08, 2026 | 49.76M |
| July 07, 2026 | 47.75M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Spyre Therapeutics, Inc. | 7.011B |
| ACADIA Pharmaceuticals, Inc. | 3.724B |
| Alnylam Pharmaceuticals, Inc. | 31.54B |
| Anika Therapeutics, Inc. | 266.68M |
| Savara, Inc. | 937.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.05M |
| Total Expenses (Quarterly) | 13.05M |
| EPS Diluted (Quarterly) | -1.052 |
| Earnings Yield | -3.46% |
| Normalized Earnings Yield | -3.466 |